Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
38 hedge funds and large institutions have $29.5M invested in Merrimack Pharmaceuticals, Inc. in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 4 closing their positions.
3% less funds holding
Funds holding: 39 → 38 (-1)
21% less capital invested
Capital invested by funds: $37.3M → $29.5M (-$7.75M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
82% less call options, than puts
Call options by funds: $180K | Put options by funds: $990K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$118K |
| 2 |
RCM
Radnor Capital Management
Wayne,
Pennsylvania
|
+$57.9K |
| 3 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$55.6K |
| 4 |
BlackRock
New York
|
+$7K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$421K |
| 2 |
Renaissance Technologies
New York
|
-$187K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$152K |
| 4 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$65K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$51K |
MACK Hedge Fund Activity: Q4 2021 in Review
38 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2021, worth a combined $29.5M — down 21% from $37.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MACK and 3 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $118K. The largest seller was Western Standard LLC, cutting an estimated $421K.
- 38 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2021, down from 39 in Q3 2021.
- Funds reported $29.5M of Merrimack Pharmaceuticals, Inc. stock for Q4 2021, down 21% quarter-over-quarter.
- 3 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2021 and 4 closed out, a net change of -1 holder.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2021 was Susquehanna International Group, an estimated $118K added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2021 was Western Standard LLC, an estimated $421K sold.
Based on aggregated 13F filings for Q4 2021.